Heart failure & cardiomyopathies
Real-World Characteristics and Treatment of Cardiac Transthyretin Amyloidosis: A Multicentre, Observational Study
Authors' conclusion
Wild-type ATTR was the primary aetiology amongst contemporary ATTR-CM patients and almost two-thirds of patients were in an advanced disease stage. Clinical profiles of 64% of patients in routine care matched those of the ATTR-ACT.
Study context
- Population
- ATTR-CM patients seen at 8 German university hospitals in first year after tafamidis 61 mg approval (April 2020 to March 2021)median age 79, 84% male
- Participants
- 366 participants
- Exposure
- Tafamidis 61 mg vs no treatment
- Outcome
- Characterization of contemporary ATTR-CM patients, potential ATTR-ACT eligibility and factors associated with tafamidis 61 mg treatment decision
Methodological detailsmulticentre, 8 university hospitals
- Multicentre
- 8 university hospitals
Main finding
As reported in the abstract
- NAC ATTR stage ≥ II
- 47%
- NYHA class ≥ III
- 45%
- Met key ATTR-ACT eligibility criteria
- 64%
- Variant ATTR, diagnosed ≤6 months vs >6 months ago (significantly lower)
- 9.3% vs. 19.7%
- Tafamidis 61 mg newly initiated among 293 without prior ATTR specific treatment
- 77%
- Treated patients younger, more often ATTR-ACT eligible, lower NYHA class, higher serum albumin; variance of treatment decision explained
- 16%
Observational data: associations, not effects.
Further findings
Unadjusted 1-year survival · unadjusted
P < 0.001
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Real-World Characteristics and Treatment of Cardiac Transthyretin Amyloidosis: A Multicentre, Observational Study. ESC Heart Fail. Published 6 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →